Advanced tumors
Conditions
Brief summary
Overall Survival (OS)
Detailed description
Modified Progression Free Survival (PFS) Per Evaluation Criteria Used in the Parent Trial, Modified Event Free Survival (EFS) Per Evaluation Criteria Used in the Parent Trial, Number of Participants Who Experience Serious Adverse Events (SAEs), Number of Participants Who Experience Adverse Events of Special Interest (AEOSI), Number of Participants Who Experience Clinically Significant Adverse Events (CSAE), Number of Participants Who Experience Events of Clinical Interest (ECI), Number of Participants Who Discontinue Study Treatment Due to an AE
Interventions
DRUGLenvatinib
DRUGfavezelimab
DRUGMK-4280A
DRUGOlaparib
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Modified Progression Free Survival (PFS) Per Evaluation Criteria Used in the Parent Trial, Modified Event Free Survival (EFS) Per Evaluation Criteria Used in the Parent Trial, Number of Participants Who Experience Serious Adverse Events (SAEs), Number of Participants Who Experience Adverse Events of Special Interest (AEOSI), Number of Participants Who Experience Clinically Significant Adverse Events (CSAE), Number of Participants Who Experience Events of Clinical Interest (ECI), Number of Participants Who Discontinue Study Treatment Due to an AE | — |
Countries
Austria, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden
Outcome results
None listed